表紙
市場調査レポート

血友病A:パイプライン分析

Hemophilia A - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232826
出版日 ページ情報 英文 159 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
血友病A:パイプライン分析 Hemophilia A - Pipeline Review, H1 2016
出版日: 2016年05月25日 ページ情報: 英文 159 Pages
概要

血友病 A はX染色体連鎖劣性欠損症で、血液の凝固第VIII因子(FVIII)の不足によって引き起こされ、遺伝あるいは自然突然変異によって発症します。 FVIII活動のレベルに応じて、血友病患者は、あざができやすかったり、外傷を受けても十分に凝固しなかったりし、重度の血友病では自発性出血を伴います。 症状は、痛みと腫れを伴う関節内出血や血尿・血便、あざ、消化管と尿路からの出血、鼻血、切り傷や抜歯、手術の際の長引く出血、突発性出血などが挙げられます。

当レポートでは、血友病Aの治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

血友病 A 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Alnylam Pharmaceuticals, Inc.
  • Amarna Therapeutics B.V.
  • Apitope International NV
  • Baxalta Incorporated
  • Bayer AG
  • Biogen, Inc.
  • BioMarin Pharmaceutical Inc.
  • Catalyst Biosciences, Inc.
  • CSL Limited
  • DBV Technologies S.A.
  • Dimension Therapeutics, Inc.
  • Emergent BioSolutions Inc.
  • EpiVax, Inc.
  • Expression Therapeutics LLC
  • F. Hoffmann-La Roche Ltd.
  • Green Cross Corporation
  • Idogen AB
  • Lentigen Technology, Inc.
  • mAbxience S.A.
  • Novo Nordisk A/S
  • Octapharma AG
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Pharming Group N.V.
  • rEVO Biologics, Inc.
  • Sangamo BioSciences, Inc.
  • SK Chemicals Co., Ltd.
  • Spark Therapeutics, Inc.
  • The International Biotechnology Center (IBC) Generium
  • UniQure N.V.

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8018IDB

Summary

Global Markets Direct's, 'Hemophilia A - Pipeline Review, H1 2016', provides an overview of the Hemophilia A pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hemophilia A, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hemophilia A and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hemophilia A
  • The report reviews pipeline therapeutics for Hemophilia A by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hemophilia A therapeutics and enlists all their major and minor projects
  • The report assesses Hemophilia A therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hemophilia A

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hemophilia A
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hemophilia A pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hemophilia A Overview
  • Therapeutics Development
    • Pipeline Products for Hemophilia A - Overview
    • Pipeline Products for Hemophilia A - Comparative Analysis
  • Hemophilia A - Therapeutics under Development by Companies
  • Hemophilia A - Therapeutics under Investigation by Universities/Institutes
  • Hemophilia A - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Hemophilia A - Products under Development by Companies
  • Hemophilia A - Products under Investigation by Universities/Institutes
  • Hemophilia A - Companies Involved in Therapeutics Development
    • Alnylam Pharmaceuticals, Inc.
    • Amarna Therapeutics B.V.
    • Apitope International NV
    • Baxalta Incorporated
    • Bayer AG
    • Biogen, Inc.
    • BioMarin Pharmaceutical Inc.
    • Catalyst Biosciences, Inc.
    • CSL Limited
    • DBV Technologies S.A.
    • Dimension Therapeutics, Inc.
    • Emergent BioSolutions Inc.
    • EpiVax, Inc.
    • Expression Therapeutics LLC
    • F. Hoffmann-La Roche Ltd.
    • Green Cross Corporation
    • Idogen AB
    • Lentigen Technology, Inc.
    • mAbxience S.A.
    • Novo Nordisk A/S
    • Octapharma AG
    • OPKO Health, Inc.
    • Pfizer Inc.
    • Pharming Group N.V.
    • rEVO Biologics, Inc.
    • Sangamo BioSciences, Inc.
    • SK Chemicals Co., Ltd.
    • Spark Therapeutics, Inc.
    • The International Biotechnology Center (IBC) Generium
    • UniQure N.V.
  • Hemophilia A - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • antihemophilic factor - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • antihemophilic factor (human) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • antihemophilic factor (recombinant) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • antihemophilic factor (recombinant) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • antihemophilic factor (recombinant) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • antihemophilic factor (recombinant) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • antihemophilic factor (recombinant) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • antihemophilic factor (recombinant) biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATXF-8117 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BAX-826 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BAX-888 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BAY-1093884 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BMN-270 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CB-813d - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy to Target Coagulation Factor VIII for Hemophilia A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • coagulation factor VIIa (recombinant) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • coagulation factor VIII (human) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • concizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CSL-689 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • damoctocog alfa pegol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Deimmunized FVIII - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DTX-201 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • emicizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ET-3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • factor VIII (recombinant) biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fitusiran - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Bleeding and Clotting Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Hemophilia A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate Factor VIII for Hemophilia A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IN-3012 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Kovaltry - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LG-889 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LR-769 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MOD-5014 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PF-06741086 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Factor VIII Replacement for Hemophilia A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Factor VIII Replacement for Hemophilia A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Hemophilia A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Proteins for Hemophilia A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SB-FVIII - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SPK-FVIII - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SVF-VIIa - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • turoctocog alfa pegol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Hemophilia A - Recent Pipeline Updates
  • Hemophilia A - Dormant Projects
  • Hemophilia A - Discontinued Products
  • Hemophilia A - Product Development Milestones
    • Featured News & Press Releases
      • May 07, 2016: Dimension Therapeutics Announces Preclinical Data From Bayer-Partnered Hemophilia A Program At American Society For Gene And Cell Therapy (ASGCT) Annual Meeting
      • Apr 18, 2016: Dimension Therapeutics announces preclinical data on hemophilia A program at upcoming American Society For Gene And Cell Therapy (ASGCT) annual meeting
      • Apr 04, 2016: Baxalta Expands Global Reach of ADYNOVATE for Hemophilia A Patients with Approval in Japan
      • Mar 17, 2016: Bayer Receives FDA Approval for Kovaltry for the Treatment of Children and Adults with Hemophilia A
      • Mar 04, 2016: Baxalta Commences Phase 1 Clinical Trial of BAX 826, the Company's Second Extended Half-Life Factor VIII Treatment for Hemophilia A
      • Mar 02, 2016: Baxalta Submits Marketing Authorization Application to the European Medicines Agency for ADYNOVI for Treatment of Hemophilia A Patients
      • Feb 25, 2016: Baxalta Announces Submission of Supplemental BLAs to Expand Use of ADYNOVATE to Pediatric Patients and Surgical Settings
      • Feb 23, 2016: OPKO Health Announces Dosing of First Patient in Phase 2a Clinical Study of a Long-Acting Factor VIIa for the Treatment of Hemophilia
      • Feb 22, 2016: Bayer Receives EU Approval of Kovaltry for Treatment of Hemophilia A
      • Feb 03, 2016: Health Canada Approves New Treatment Option For Canadian Adults and Children Living with Hemophilia A
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hemophilia A, H1 2016
  • Number of Products under Development for Hemophilia A - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Hemophilia A - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016
  • Hemophilia A - Pipeline by Amarna Therapeutics B.V., H1 2016
  • Hemophilia A - Pipeline by Apitope International NV, H1 2016
  • Hemophilia A - Pipeline by Baxalta Incorporated, H1 2016
  • Hemophilia A - Pipeline by Bayer AG, H1 2016
  • Hemophilia A - Pipeline by Biogen, Inc., H1 2016
  • Hemophilia A - Pipeline by BioMarin Pharmaceutical Inc., H1 2016
  • Hemophilia A - Pipeline by Catalyst Biosciences, Inc., H1 2016
  • Hemophilia A - Pipeline by CSL Limited, H1 2016
  • Hemophilia A - Pipeline by DBV Technologies S.A., H1 2016
  • Hemophilia A - Pipeline by Dimension Therapeutics, Inc., H1 2016
  • Hemophilia A - Pipeline by Emergent BioSolutions Inc., H1 2016
  • Hemophilia A - Pipeline by EpiVax, Inc., H1 2016
  • Hemophilia A - Pipeline by Expression Therapeutics LLC, H1 2016
  • Hemophilia A - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Hemophilia A - Pipeline by Green Cross Corporation, H1 2016
  • Hemophilia A - Pipeline by Idogen AB, H1 2016
  • Hemophilia A - Pipeline by Lentigen Technology, Inc., H1 2016
  • Hemophilia A - Pipeline by mAbxience S.A., H1 2016
  • Hemophilia A - Pipeline by Novo Nordisk A/S, H1 2016
  • Hemophilia A - Pipeline by Octapharma AG, H1 2016
  • Hemophilia A - Pipeline by OPKO Health, Inc., H1 2016
  • Hemophilia A - Pipeline by Pfizer Inc., H1 2016
  • Hemophilia A - Pipeline by Pharming Group N.V., H1 2016
  • Hemophilia A - Pipeline by rEVO Biologics, Inc., H1 2016
  • Hemophilia A - Pipeline by Sangamo BioSciences, Inc., H1 2016
  • Hemophilia A - Pipeline by SK Chemicals Co., Ltd., H1 2016
  • Hemophilia A - Pipeline by Spark Therapeutics, Inc., H1 2016
  • Hemophilia A - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016
  • Hemophilia A - Pipeline by UniQure N.V., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Hemophilia A Therapeutics - Recent Pipeline Updates, H1 2016
  • Hemophilia A - Dormant Projects, H1 2016
  • Hemophilia A - Dormant Projects (Contd..1), H1 2016
  • Hemophilia A - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Hemophilia A, H1 2016
  • Number of Products under Development for Hemophilia A - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top